semaglutide injection compounded FDA alerts health care providers, compounders and patients of dosing errors associated with injectable products FDA issues warning about some
Description
JAMA Netw Open 7: e2350408, 2024

Schulz et al., 2023), none has focused specifically on cue-induced brain responses measured with task-based fMRI, the neural signals most relevant to understanding how GLP-1 RAs might reduce the motivational pull of rewarding stimuli, or critically evaluated the methodological approaches in this emerging literature

Cardiovasc Contin

They are considerations to discuss with your prescriber, not personalized recommendations

While this finding has not been confirmed in humans during extensive clinical trials and post-marketing surveillance, the FDA requires a boxed warning on GLP-1 receptor agonist labels regarding this potential risk

(2015) Novel allosteric modulators of G protein-coupled receptors
